Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

References

• Grundman M, Thal LJ. Treatment of Alzheimer’s disease: rationale and strategies. Neurol Clin 2000;18:807–28
   PubMed Web of Science ®Google Scholar
• Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60: 1119–22
   Google Scholar
• National Center for Health Statistics. Alzheimer’s disease. National Nursing Home Survey. 1999 Summary. Available at www.cdc.gov/nchs/fastats/alzheimr.htm. Accessed 10/6/2003
   Google Scholar
• Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590–9
   PubMed Web of Science ®Google Scholar
• Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology 1996;46:130–5
   PubMed Web of Science ®Google Scholar
• Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer’s disease. Am J Psychiatry 1998;155: 1512–20
   PubMed Web of Science ®Google Scholar
• Lyketsos CG, Sheppard JM, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 2001;16:1043–53
   PubMed Web of Science ®Google Scholar
• Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. Prog Brain Res 1993;98:431–8
   Google Scholar
• Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomized controlled trial. Br Med J 1999;318:633–8
   Google Scholar
• Corey-Bloom J, Anand R, Veach, et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998;1:55–65
   Google Scholar
• Burns A, Spiegel R, Quaig P. Benefits of rivastigmine in patients with severe Alzheimer’s disease (AD). Poster presented at: 41st annual meeting of the American College of Neuropsychopharmacology, December 8–12, 2002, San Juan Puerto Rico. [Poster 173]
   Google Scholar
• McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: results of a randomized, double-blind, placebo-controlled international study. Lancet 2000;356:2031–6
   PubMed Web of Science ®Google Scholar
• Cummings JL, Anand R, Koumaras B, et al. Rivastigmine provides behavioural benefits to Alzheimer’s disease patients residing in a nursing home: findings from a 26-week trial. Neurology 2000;54:A468 [Abstract S79.002]
   Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44
   PubMed Web of Science ®Google Scholar
• Wood S, Cummings JL, Hsu MA, et al. The use of the neuro-psychiatric inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry 2000;8:75–83
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
   Google Scholar
• Reisberg B, Franssen E, Sclan SG, Kluger A, Ferris SH. Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer’s disease. Bull Clin Neurosci 1989;54:95–112
   Google Scholar
• Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141: 1356–1364
   PubMed Web of Science ®Google Scholar
• Delagarza VW. Pharmacologic treatment of Alzheimer’s disease: an update. Am Fam Physician 2003;68(7):1365–72
   PubMed Web of Science ®Google Scholar
• Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer’s disease. Gerontology 1999;45(Suppl 1):15–22
   Google Scholar
• Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer’s disease. Int J Neuropsychopharmacol 2001;4: 223–230
   PubMed Web of Science ®Google Scholar
• Edwards K, Mirski D, Koumaras B, Gunay I Rivastigmine Reduces Need For Antipsychotics and Other Psychotropic Medications in Nursing Home Patients with Alzheimer’s Disease (manuscript in progress)
   Google Scholar